Imeron

Iomeprol, the active ingredient in Imeron, is an iodinated contrast media presented as a solution for injection for intra‑arterial, intravenous or intrathecal use. It enhances radiographic imaging by increasing the visibility of vascular and tissue structures during diagnostic procedures. It is used in patients undergoing angiography, computed tomography, urography, arthrography and myelography to provide clear delineation of anatomical structures.

GNH USA supplies Imeron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide, adhering to EU quality standards.

Imeron is employed as an iodinated contrast agent to improve visualization of vascular and tissue structures in various imaging modalities.

- Angiography: Enhances the delineation of blood vessels, aiding diagnosis and interventional planning. - Computed tomography (CT) imaging: Increases contrast between tissues, facilitating detection of lesions and anatomical detail. - Urography: Improves visualization of the urinary tract, supporting assessment of renal function and obstruction. - Arthrography: Provides clear joint space contrast for evaluation of cartilage and intra‑articular structures. - Myelography: Highlights the spinal canal and nerve roots to assist in diagnosing spinal pathology.

Adverse reactions to Imeron may range from mild to severe and are reported in clinical practice.

Common Side Effects: - Warm sensation or flushing at injection site. - Nausea or vomiting. - Mild headache. - Transient metallic taste. - Low‑grade hypotension. - Warmth or itching of the skin.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Acute kidney injury, especially in patients with pre‑existing renal impairment. - Cardiac arrhythmias. - Pulmonary edema. - Seizures. - Severe hypotension or shock.

Before using Imeron, clinicians should assess patient risk factors and follow recommended safety measures. - Renal function: Evaluate serum creatinine and eGFR, especially in patients with chronic kidney disease. - Allergy history: Screen for prior reactions to iodinated contrast agents or shellfish allergy. - Hydration: Ensure adequate patient hydration before and after administration to reduce nephrotoxicity risk. - Thyroid status: Use caution in patients with hyperthyroidism or thyroid disorders. - Concomitant nephrotoxic drugs: Avoid or monitor use of NSAIDs, aminoglycosides, or other renal‑impairing agents. - Pregnancy: Use only if essential; category B2 indicates limited data, weigh benefits versus potential fetal exposure. - Store below 25°C: Keep in original packaging, protect from light and moisture.

Imeron may interact with other medicines, affecting safety or diagnostic accuracy.

Major Interactions (Avoid): - Metformin: Risk of lactic acidosis; discontinue metformin before contrast administration and resume after renal function is confirmed. - High‑dose iodinated drugs (e.g., amiodarone): May increase iodine load and thyroid dysfunction risk. - ACE inhibitors or ARBs: Potential for worsening renal function; consider temporary suspension.

Moderate Interactions (Monitor Closely): - Diuretics: May potentiate volume depletion and renal impairment. - NSAIDs: Can reduce renal perfusion, increasing risk of contrast‑induced nephropathy. - Beta‑blockers: May mask signs of contrast‑induced hypertension. - Thyroid hormone replacement: Monitor thyroid function tests after contrast exposure. - Radiopharmaceuticals: May interfere with imaging interpretation; coordinate timing.